October 2, 2022

Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.

The oncology community has enjoyed success to a large degree through the existing NIH and NCI mechanisms. Will they ask how can they work with us in a concerted fashion to benefit new discoveries, novel translation in well-designed clinical trials, and eventual development of exciting, more effective cancer therapies for patients?